Publications

BibTex format

@article{Chan:2022:10.1016/j.cjtee.2021.10.005,
author = {Chan, G and Narang, A and Aframian, A and Ali, Z and Bridgeman, J and Carr, A and Chapman, L and Goodier, H and Morgan, C and Park, C and Sexton, S and Sugand, K and Walton, T and Wilson, M and Belgaumkar, A and Gallagher, K and Ghosh, K and Gibbons, C and Jacob, J and Keightley, A and Nawaz, Z and Sarraf, K and Wakeling, C and Kieffer, W and Rogers, B},
doi = {10.1016/j.cjtee.2021.10.005},
journal = {Chinese Journal of Traumatology},
pages = {161--165},
title = {Medium-term mortality after hip fractures and COVID-19: A prospective multi-centre UK study},
url = {http://dx.doi.org/10.1016/j.cjtee.2021.10.005},
volume = {25},
year = {2022}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - PurposeThe COVID-19 pandemic has caused 1.4 million deaths globally and is associated with a 3–4 times increase in 30-day mortality after a fragility hip fracture with concurrent COVID-19 infection. Typically, death from COVID-19 infection occurs between 15 and 22 days after the onset of symptoms, but this period can extend up to 8 weeks. This study aimed to assess the impact of concurrent COVID-19 infection on 120-day mortality after a fragility hip fracture.MethodsA multi-centre prospective study across 10 hospitals treating 8% of the annual burden of hip fractures in England between 1st March and 30th April, 2020 was performed. Patients whose surgical treatment was payable through the National Health Service Best Practice Tariff mechanism for “fragility hip fractures” were included in the study. Patients’ 120-day mortality was assessed relative to their peri-operative COVID-19 status. Statistical analysis was performed using SPSS version 27.ResultsA total of 746 patients were included in this study, of which 87 (11.7%) were COVID-19 positive. Mortality rates at 30- and 120-day were significantly higher for COVID-19 positive patients relative to COVID-19 negative patients (p < 0.001). However, mortality rates between 31 and 120-day were not significantly different (p = 0.107), 16.1% and 9.4% respectively for COVID-19 positive and negative patients, odds ratio 1.855 (95% CI 0.865–3.978).ConclusionHip fracture patients with concurrent COVID-19 infection, provided that they are alive at day-31 after injury, have no significant difference in 120-day mortality. Despite the growing awareness and concern of “long-COVID” and its widespread prevalence, this does not appear to increase medium-term mortality rates after a hip fracture.
AU  - Chan,G
AU  - Narang,A
AU  - Aframian,A
AU  - Ali,Z
AU  - Bridgeman,J
AU  - Carr,A
AU  - Chapman,L
AU  - Goodier,H
AU  - Morgan,C
AU  - Park,C
AU  - Sexton,S
AU  - Sugand,K
AU  - Walton,T
AU  - Wilson,M
AU  - Belgaumkar,A
AU  - Gallagher,K
AU  - Ghosh,K
AU  - Gibbons,C
AU  - Jacob,J
AU  - Keightley,A
AU  - Nawaz,Z
AU  - Sarraf,K
AU  - Wakeling,C
AU  - Kieffer,W
AU  - Rogers,B
DO  - 10.1016/j.cjtee.2021.10.005
EP  - 165
PY  - 2022///
SN  - 1008-1275
SP  - 161
TI  - Medium-term mortality after hip fractures and COVID-19: A prospective multi-centre UK study
T2  - Chinese Journal of Traumatology
UR  - http://dx.doi.org/10.1016/j.cjtee.2021.10.005
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000805636000007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
UR  - https://www.sciencedirect.com/science/article/pii/S1008127521001802?via%3Dihub
UR  - http://hdl.handle.net/10044/1/101808
VL  - 25
ER  -

Download

Dr Kapil Sugand

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)